Revance Therapeutics has raised $45 million in a new round of venture capital funding. The new financing was led by Essex Woodlands Health Ventures, NovaQuest Capital and CNF Investments. The biopharmaceutical company’s existing backers include Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors and Pac-Link Ventures. As part of the deal, Jonathan Tunnicliffe, partner at NovaQuest will join the Revance board of directors.
Click here for the release from Business Wire.